ABSTRACT
An 81-year-old male with myasthenia gravis developed a cutaneous infection with Mycobacterium marinum, which apparently resolved following local heat therapy. Five months later, the patient developed new skin lesions and pancytopenia. M. marinum was isolated from his bone marrow. Pulsed-field gel electrophoresis was performed to determine if the skin and bone marrow isolates were clonally related. Digestion of the genomic DNA with the restriction enzymes SpeI and AseI yielded indistinguishable banding patterns. An epidemiologically unrelated control strain showed significant banding differences. The results suggest that the patient's recurrent, disseminated infection was due to recrudescence of his initial infection rather than reinfection by another strain.
Subject(s)
Mycobacterium Infections, Nontuberculous/etiology , Mycobacterium marinum/isolation & purification , Aged , Aged, 80 and over , DNA, Bacterial/analysis , Electrophoresis, Gel, Pulsed-Field , Humans , Immunocompromised Host , Male , Mycobacterium Infections, Nontuberculous/diagnosis , RecurrenceABSTRACT
A cross-sectional study was conducted to assess the prevalence and microbiology of oral infection due to fluconazole-resistant Candida in patients with AIDS. Oral swab specimens for fungal cultures were obtained from 100 consecutive outpatients with CD4 lymphocyte counts of < 200/mm3. At least one fungal organism demonstrating in vitro resistance to fluconazole (minimum inhibitory concentration, > or = 8 micrograms/mL) was isolated from 26 (41%) of 64 patients for whom cultures were positive. When fluconazole-resistant C. albicans was isolated, in vitro resistance correlated with clinical thrush. None of 10 patients from whom only non-albicans species of Candida were isolated had active thrush. The patients from whom fluconazole-resistant Candida albicans was isolated had lower CD4 cell counts (median, 9/mm3), a greater number of treated episodes of thrush (median, 4.5), and a greater median duration of prior fluconazole treatment (231 days) than did patients from whom fluconazole-susceptible C. albicans was isolated (median CD4 cell count, 58/mm3 [P = .004]; median number of treated episodes of thrush, 2.0 [P = .001]; and median duration of prior fluconazole treatment, 10 days [P = .01]; respectively). In a multivariate analysis, the number of episodes and duration of fluconazole therapy were independent predictors of resistance.
